StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Adaptimmune Therapeutics's operating cash flow for the twelve months ending Jun 30, 2025 was -$190.03M. For fiscal 2024 it was -$73.21M. The highest annual figure on record is $36.84M in fiscal 2014.

Annual operating cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$73.21M–
FY2023Dec 31, 2023-$140.88M–
FY2022Dec 31, 2022-$141.77M-1421.4%
FY2021Dec 31, 2021$10.73M–
FY2020Dec 31, 2020-$53.59M–
FY2019Dec 31, 2019-$112.51M–
FY2018Dec 31, 2018-$104.39M–
FY2017Dec 31, 2017-$54.32M–
FY2015Jun 30, 2015-$29.67M-180.5%
FY2014Jun 30, 2014$36.84M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2025CQ2 2025Jun 30, 2025-$34.78M-173.4%
Q1 FY2025CQ1 2025Mar 31, 2025-$66.59M–
Q4 FY2024CQ4 2024Dec 31, 2024-$34.20M–
Q3 FY2024CQ3 2024Sep 30, 2024-$54.45M–
Q2 FY2024CQ2 2024Jun 30, 2024$47.40M–
Q1 FY2024CQ1 2024Mar 31, 2024-$31.95M–
Q4 FY2023CQ4 2023Dec 31, 2023-$14.68M-818.7%
Q3 FY2023CQ3 2023Sep 30, 2023-$45.16M–
Q2 FY2023CQ2 2023Jun 30, 2023-$43.76M–
Q1 FY2023CQ1 2023Mar 31, 2023-$37.28M–
Q4 FY2022CQ4 2022Dec 31, 2022$2.04M-98.5%
Q3 FY2022CQ3 2022Sep 30, 2022-$48.16M–
Q2 FY2022CQ2 2022Jun 30, 2022-$41.25M–
Q1 FY2022CQ1 2022Mar 31, 2022-$54.40M–
Q4 FY2021CQ4 2021Dec 31, 2021$133.93M–
Q3 FY2021CQ3 2021Sep 30, 2021-$45.20M–
Q2 FY2021CQ2 2021Jun 30, 2021-$31.46M–
Q1 FY2021CQ1 2021Mar 31, 2021-$46.54M-376.1%
Q4 FY2020CQ4 2020Dec 31, 2020-$29.22M–
Q3 FY2020CQ3 2020Sep 30, 2020-$16.32M–
Q2 FY2020CQ2 2020Jun 30, 2020-$24.92M–
Q1 FY2020CQ1 2020Mar 31, 2020$16.86M–
Q4 FY2019CQ4 2019Dec 31, 2019-$12.53M–
Q3 FY2019CQ3 2019Sep 30, 2019-$29.61M-397.9%
Q2 FY2019CQ2 2019Jun 30, 2019-$34.17M–
Q1 FY2019CQ1 2019Mar 31, 2019-$36.20M–
Q4 FY2018CQ4 2018Dec 31, 2018-$31.69M–
Q3 FY2018CQ3 2018Sep 30, 2018$9.94M-26.3%
Q2 FY2018CQ2 2018Jun 30, 2018-$35.36M–
Q1 FY2018CQ1 2018Mar 31, 2018-$47.28M–
Q4 FY2017CQ4 2017Dec 31, 2017-$21.36M–
Q3 FY2017CQ3 2017Sep 30, 2017$13.49M–
Q2 FY2017CQ2 2017Jun 30, 2017-$18.01M–
Q1 FY2017CQ1 2017Mar 31, 2017-$28.44M–
Q3 FY2015CQ1 2015Mar 31, 2015-$5.64M–

More Adaptimmune Therapeutics figures

See a number that looks wrong?